Cerity Partners
AKTX

Cerity Partners’s Akari Therapeutics AKTX Stock Holding History

Cerity Partners’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-591
Closed -$6.83K – 3238
2025
Q4 		$6.83K Hold
591
– – ﹤0.01% 2867
2025
Q3 		$23.9K Hold
591
– – ﹤0.01% 2721
2025
Q2 		$27.7K Hold
591
– – ﹤0.01% 2595
2025
Q1 		$29.3K Hold
591
– – ﹤0.01% 2428
2024
Q4 		$28.8K Hold
591
– – ﹤0.01% 2395
2024
Q3 		$69.7K Hold
591
– – ﹤0.01% 2457
2024
Q2 		$63.8K Hold
591
– – ﹤0.01% 2150
2024
Q1 		$44.1K Hold
591
– – ﹤0.01% 2252
2023
Q4 		$73.8K Hold
591
– – ﹤0.01% 1801
2023
Q3 		$93.4K Buy
591
+187
+46% +$28.9K ﹤0.01% 1335
2023
Q2 		$54.9K Buy
+404
New +$58.4K ﹤0.01% 1568

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Cerity Partners's AKTX Position: Q1 2026 in Review

Cerity Partners sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 591 shares — an estimated $6.83K sold.

Cerity Partners first reported a position in AKTX in Q2 2023 and held it in 11 quarters. The position peaked at $93.4K in Q3 2023. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Cerity Partners reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cerity Partners sold 591 Akari Therapeutics shares in Q1 2026, an estimated $6.83K.
  • Cerity Partners first reported a position in Akari Therapeutics in Q2 2023 and held it in 11 quarters.
  • Cerity Partners's Akari Therapeutics position peaked at $93.4K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.